PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial

Abstract excerpt

Abstract Purpose: Genomic alterations in key components of PI3K/mTOR pathway have been proposed as candidate predictive markers for rapalog therapy in renal cell carcinoma (RCC). We tested this hypothesis in patients from a randomized phase II trial of everolimus versus sunitinib. Patients and Methods: Archival specimens collected at baseline were analyzed with targeted next-generation sequencing (NGS). Focus of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to PI3K/AKT/mTOR signaling in cancer
• Share to Renal cell carcinoma treatment
• Share to Tuberous Sclerosis Complex Research